Interleukin-12 Antagonists as New Therapeutic Agents in Inflammatory Bowel Disease

Publisher： Karger

E-ISSN： 1423-0291|70|3|177-183

ISSN： 1015-2008

Source： Pathobiology, Vol.70, Iss.3, 2003-02, pp. : 177-183

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-Interleukin-18 Therapy in Murine Models of Inflammatory Bowel Disease

By  

Pathobiology, Vol. 70, Iss. 3, 2003-02 ,pp. : 164-169

Karger

Access to resources Recommend Favorite

Animal Models of Inflammatory Bowel Disease: An Overview

By  

Pathobiology, Vol. 70, Iss. 3, 2003-02 ,pp. : 121-130

Karger

Access to resources Recommend Favorite

Role of Gamma Delta T Cells in Inflammatory Bowel Disease

By  

Pathobiology, Vol. 70, Iss. 3, 2003-02 ,pp. : 150-155

Karger

Access to resources Recommend Favorite

Negative Regulators of Angiogenesis in Inflammatory Bowel Disease: Thrombospondin in the Spotlight

By  

Pathobiology, Vol. 75, Iss. 1, 2008-03 ,pp. : 22-24

Karger

Access to resources Recommend Favorite

Environment as a Critical Factor for the Pathogenesis and Outcome of Gastrointestinal Disease: Experimental and Human Inflammatory Bowel Disease and Helicobacter-Induced Gastritis

By  

Pathobiology, Vol. 72, Iss. 6, 2006-03 ,pp. : 293-307

Karger

Access to resources Recommend Favorite